The U.S. CMO/CDMO market is experiencing robust growth, poised to reach an estimated valuation of US$149.4 billion by 2032, up from US$83.1 billion in 2025. This growth is fueled by the increasing demand for diverse services, including Active Pharmaceutical Ingredient (API) manufacturing, formulation development, and packaging services, which are essential to both the pharmaceutical and biopharmaceutical sectors. With an expected compound annual growth rate (CAGR) of 8.7% between 2025 and 2032, the market’s trajectory reflects the expanding role of outsourcing within the biopharma industry, driven by the need for cost-efficiency, innovation, and rapid commercialization of complex therapies.
Key Market Trends and Growth Drivers
The growth of the U.S. CMO/CDMO market is underpinned by several significant factors. One of the most notable drivers is the shift in the pharmaceutical industry towards outsourcing manufacturing and development services to CDMOs. This trend offers substantial cost savings by eliminating the need for upfront capital investment in Good Manufacturing Practice (GMP)-compliant facilities, which can be costly and underutilized. CDMOs provide a strategic solution by reducing the risks associated with idle manufacturing capacity while enabling faster commercialization of niche and orphan therapies. This approach allows biopharma companies, particularly emerging small and mid-sized firms, to focus on core research and development activities, thereby accelerating time-to-market for innovative therapies.
Additionally, the demand for advanced therapies such as gene therapies, cell-based treatments, mRNA vaccines, and viral vectors is a key growth driver. The complexity of manufacturing these therapies requires specialized capabilities that many biopharma companies lack in-house. CDMOs with the required expertise and infrastructure are stepping in to fill this gap, offering bioprocessing, fill-finish services, and complex drug formulation. This partnership allows for faster and more efficient production, ultimately contributing to market growth.
The oncology therapeutic area is a particularly strong growth segment within the U.S. CMO/CDMO market. With an increasing number of targeted biologics and cell-based therapies aimed at cancer treatment, CDMOs are uniquely positioned to assist in the transition from drug development to commercial manufacturing. The high R&D investment and expanding clinical pipeline in oncology continue to boost demand for outsourced manufacturing services.
Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/35634
Key Highlights from the Report:
• U.S. CMO/CDMO market size projected to reach US$149.4 billion by 2032
• API manufacturing services dominate market share, with high-volume production for small molecules
• Oncology remains the leading therapeutic area for CMO/CDMO services
• Rapid growth of emerging biopharma firms creates substantial opportunities for CDMOs
• Outsourcing to CDMOs allows for cost-effective and accelerated commercialization
• Mergers and acquisitions are reshaping the competitive landscape, expanding service offerings
Market Segmentation
The U.S. CMO/CDMO market can be segmented based on service type, therapeutic area, and end-user. Within the service type category, API manufacturing holds the largest share. API manufacturing remains the backbone of the CMO/CDMO industry, as it involves large-scale production of active pharmaceutical ingredients for small molecules, which are essential in the development of both generic and branded drugs. Outsourcing API manufacturing is a cost-effective solution, as it allows biopharma companies to access state-of-the-art facilities without incurring the high capital expenditure required to build and maintain GMP-compliant manufacturing plants.
In terms of therapeutic areas, oncology leads the way, with a significant portion of demand driven by the shift towards biologics and cell-based therapies. CDMOs that specialize in handling complex biological drugs are critical in supporting the growing oncology pipeline. As cancer therapies become more targeted and personalized, the need for specialized manufacturing capabilities grows. This market segment also benefits from high levels of R&D investment, as both public and private sectors strive to bring innovative cancer treatments to market.
Other therapeutic areas showing strong demand include immunology and rare diseases, where precision medicine and biologics are increasingly prevalent. As new therapies emerge in these areas, the need for specialized contract manufacturing services to scale production continues to rise.
Regional Insights
The U.S. is the dominant player in the global CMO/CDMO market, not just in terms of market size but also in terms of technological innovation and service capabilities. The demand for CDMO services in the U.S. is driven by the presence of a large number of biopharma companies, many of which are at the forefront of developing cutting-edge therapies, particularly in oncology, immunology, and rare diseases. This concentration of innovation within the U.S. pharmaceutical industry makes it a hub for contract manufacturing services, with many CDMOs focusing their operations on meeting the growing needs of U.S.-based clients.
The U.S. is also home to some of the largest and most sophisticated CDMO facilities, which are increasingly being upgraded to handle advanced therapies such as gene and cell-based therapies. These facilities are located in key biopharma clusters, including the Boston-Cambridge area, San Francisco Bay Area, and San Diego, all of which are major centers for biotech innovation. As more small and mid-sized biopharma companies continue to emerge, particularly in the field of advanced therapies, the demand for specialized CDMO services is expected to remain strong across the U.S.
Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/35634
Market Drivers
Several key factors are propelling the growth of the U.S. CMO/CDMO market. The increasing complexity of drug manufacturing, particularly in the realm of biologics and advanced therapies, is a major driver. Many biopharma companies are turning to CDMOs to handle specialized manufacturing processes, such as viral vector production, mRNA vaccine fill-finish services, and cell therapy processing. CDMOs are able to provide these services at scale, enabling faster development timelines and higher production yields.
Another driver is the growing demand for cost-effective solutions within the biopharma sector. Outsourcing manufacturing and development services to CDMOs allows companies to focus their capital on research and development, while also reducing overhead costs associated with facility maintenance, regulatory compliance, and workforce training. By leveraging the capabilities of CDMOs, companies can accelerate the commercialization of their products without the financial burden of building and operating expensive production facilities.
Market Restraints
While the U.S. CMO/CDMO market is growing rapidly, several factors could hinder its expansion. One of the key challenges is the increasing operational costs associated with the biotech sector. The need for specialized talent, coupled with rising inflation in materials and logistics, is putting pressure on CDMOs to maintain profitability. In addition, the construction and validation of new GMP-compliant facilities is an expensive and time-consuming process, creating a barrier for some CDMOs looking to expand their capacity.
Furthermore, the complexity of the supply chain and reliance on a limited number of suppliers for raw materials and consumables presents significant risks. Shortages in critical supplies or delays in sourcing raw materials can disrupt production schedules, leading to increased costs and delays in product timelines. Managing these risks effectively requires careful planning and strong relationships with suppliers, but it remains a persistent challenge in the industry.
Market Opportunities
Despite the challenges, the U.S. CMO/CDMO market is rich with opportunities. The rapid expansion of emerging biopharma companies is a key area of growth. Many of these smaller firms are focusing on niche markets, such as rare diseases, and require outsourced manufacturing services to scale their operations. CDMOs are well-positioned to offer these companies end-to-end services, from drug development and bioprocessing to regulatory support and commercial manufacturing.
The increasing demand for advanced therapies, such as gene therapies, cell-based treatments, and personalized medicine, is another significant opportunity for CDMOs. These therapies require highly specialized manufacturing processes that are not typically available in-house at biopharma companies. CDMOs that can offer cutting-edge capabilities in these areas are likely to see significant growth in the coming years.
Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/35634
Company Insights
Several key players dominate the U.S. CMO/CDMO market, with a focus on providing integrated services across the drug development and manufacturing lifecycle.
• Thermo Fisher Scientific Inc.
• AGC Biologics
• Curia Global, Inc.
• LGM Pharma
• Cell Culture Company, LLC
• Ascendia Pharmaceutical Solutions
• Kindeva
• Crystal Pharmatech Co., Ltd.
• Asymchem Inc.
• Pharmaceutics International, Inc.
• Catalent, Inc.
• Cambrex Corporation
• CARBOGEN AMCIS
• Lonza
• Bora Pharmaceuticals
• BioSpring
• Quotient Sciences
• Hillgene Biopharma Co., Ltd.
• CMIC HOLDINGS Co., LTD.
• Evonik
• Novartis AG
• Piramal Pharma Limited
• CordenPharma
• Recipharm AB
Recent Developments:
In September 2025, Enzene Biosciences Ltd. opened a state-of-the-art biopharmaceutical manufacturing plant in the U.S., valued at US$50 million.
In October 2024, Lonza acquired Genentech’s biologics manufacturing site in Vacaville, California, for US$1.2 billion, enhancing its manufacturing capacity for late-stage clinical and commercial products.
Conclusion
The U.S. CMO/CDMO market is poised for continued growth, driven by the increasing complexity of pharmaceutical and biopharmaceutical manufacturing, the rapid rise of advanced therapies, and the ongoing trend toward outsourcing in the sector. With the right investments in specialized capabilities, CDMOs are set to play an integral role in helping biopharma companies bring innovative therapies to market faster and more cost-effectively. However, challenges related to operational costs and supply chain complexities remain, and companies must remain agile and adaptive to maintain their competitive edge. The future of the CMO/CDMO market looks promising, with emerging biopharma firms and advanced therapies offering substantial growth opportunities for players in the space.
